CAR T-cell therapies have transformed the therapeutic landscape for hematologic malignancies, offering substantial benefit to patients with few alternative treatment options. While these innovative therapies represent a breakthrough in immuno-oncology, their impact thus far has been limited to a small subset of patients, and challenges to development and commercialization remain a hurdle. These challenges range from narrow patient eligibility criteria and complex administration processes to off-tumor toxicity, complicated manufacturing scale-up and high costs.
There is significant potential to expand the applications of — and broaden access to — CAR T-cell therapies to address unmet needs. Opportunities exist to not only optimize the safety, efficacy and clinical potency of these treatments, but also make them more widely available to larger, more diverse patient populations.
Join the featured speaker as they explore key strategies for broadening access to CAR T-cell therapies and discuss important considerations for sponsors focused on increasing patient-centricity and diversity in clinical trials involving these novel treatments.
Dr. Ayesha A. Pandit, MD, MS, MBA, Vice President, Medical Affairs, Premier Research
Dr. Ayesha Pandit serves as Vice President, Medical Affairs, for Premier Research. A board-certified Hemato-Oncologist, Dr. Pandit brings over 20 years of oncology experience from her tenure in world-leading companies, including AbbVie, Johnson & Johnson and MD Anderson Hospital. In her role at Premier, Dr. Pandit leads and supports the global strategy for hematology/oncology clinical trials and manages high-profile clinical programs within the oncology space.
Dr. Pandit earned her MD from King Edward Medical University, Pakistan, and her residency and fellowship from King’s College London, UK. Dr. Pandit also holds an MS in molecular oncology and an MBA in healthcare management from the National University of Singapore.
Who Should Attend?
This webinar will benefit managers and above at biotech and specialty pharma companies with job functions including, but not limited, to:
- Clinical Operations
- Medical Affairs
- Project Management
- Regulatory Affairs
What You Will Learn
Attendees will gain insights into:
- Challenges, opportunities and advances in the development of CAR T-cell therapies for solid tumors
- Progress in expanding the indications and applicability of CAR T-cell therapies in hematological malignancies, such as use in earlier lines of treatment or in combination with other treatments
- Approaches to improving the safety, efficacy and cost of CAR T-cell therapies, including bi-specific chimeric antigen receptors (CARs), multi-antigen-targeted therapies, controlled CARs and allogeneic treatments
- Strategies for enhancing the patient-centricity of CAR T-cell trials and best practices for toxicity management
Premier Research, a clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions. Visit premier-research.com.